To facilitate collaboration and resource sharing within the Canadian nanomedicine research community, NMIN is pleased to provide this searchable database of nanomedicine-related expertise among established/independent Canadian professionals.
The database includes Canadian academic faculty at least at the assistant professor level, as well as other Canadian professionals in academia, industry, or regulatory agencies who have passed their probationary period. If you meet these criteria and wish to be included in the database, please provide us your information here.
The table below can be searched by any field.
All | Institution | Researcher | Nanodelivery type | Targeting approach | Application | Disease model | Protocols | Instrumentation | Auxilliary expertise |
---|---|---|---|---|---|---|---|---|---|
Researcher: Theresa M Allen Institution: University of Alberta / University of British Columbia (UBC) Nanodelivery type
Targeting approach
Application
Disease model(s)
Protocols: Safety/pharmacology |
University of Alberta / University of British Columbia (UBC) |
Theresa M Allen |
Lipid-based Polymer-based |
Active targeting: Antibody or antibody fragments; Peptide; Small molecule Physical targeting: pH sensitive |
Drug delivery: Soluble molecules; Insoluble molecules Gene delivery: mRNA/samRNA; ASO Peptide/protein delivery |
Cancer (In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) |
Safety/pharmacology |
||
Researcher: Ildiko Badea Institution: University of Saskatchewan Nanodelivery type
Targeting approach
Application
Disease model(s)
Instrumentation: Synchrotron techniques Auxiliary expertise: Other: Human research ethics |
University of Saskatchewan |
Ildiko Badea |
Lipid-based Inorganic |
Physical targeting: pH sensitive |
Drug delivery |
Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model) |
Synchrotron techniques |
Other: Human research ethics |
|
Researcher: Marc A Gauthier Institution: Institut National de la Recherche Scientifique Nanodelivery type
Targeting approach
Application
Disease model(s)
Auxiliary expertise: Non-nano delivery systems |
Institut National de la Recherche Scientifique |
Marc A Gauthier |
Polymer-based |
Active Targeting: Antibody or antibody fragments; Peptide; Aptamer |
Drug delivery: Soluble molecules |
Cancer (In vitro, In vivo xenograft model, Primary cells) Other: several diseases (In vitro, In vivo) |
Non-nano delivery systems |
||
Researcher: Ken Harder Institution: University of British Columbia (UBC) Nanodelivery type
Targeting approach
Application
Disease model(s)
Protocols: Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting Instrumentation: CyTOF Auxiliary expertise: Non-nano delivery systems |
University of British Columbia (UBC) |
Ken Harder |
Lipid-based |
Other: 5 or 6 component LNPs for immune cell specific targeting |
Gene delivery: mRNA/samRNA |
Cancer (In vitro, In vivo syngeneic model, In vivo metastatic model) Other: Alzheimer’s, obesity and atherosclerosis (In vitro, In vivo; mouse models) |
Other: CyTOF and CITE-seq protein and transcriptomic analysis of LNP targeting |
CyTOF |
Non-nano delivery systems |
Researcher: Umar Iqbal Institution: National Research Council of Canada Nanodelivery type
Targeting approach
Application
Disease model(s)
Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics |
National Research Council of Canada |
Umar Iqbal |
Lipid-based |
Active targeting: Antibody or antibody fragments; Peptide Physical targeting: Other (novel lipids and new lipid chemistry) |
Gene delivery: mRNA/samRNA; ASO |
Cancer (In vitro, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model, Human) Rare diseases (Human) |
Safety/pharmacology (Pre-GLP toxicity); Microfluidics |
||
Researcher: Jessica Kalra Institution: University of British Columbia (UBC) Nanodelivery type
Application
Disease model(s)
Protocols: Microfluidics Auxiliary expertise: Other: In vivo modelling and imaging |
University of British Columbia (UBC) |
Jessica Kalra |
Lipid-based |
Drug delivery: Soluble molecules; Insoluble molecules |
Cancer (In vitro, Organoid) Other: Neurological and inflammatory disease (In vitro, Organoid) |
Microfluidics |
Other: In vivo modelling and imaging |
||
Researcher: Sherry Leung Institution: Precision NanoSystems Nanodelivery type
Targeting approach
Protocols: Microfluidics |
Precision NanoSystems |
Sherry Leung |
Lipid-based |
Gene therapy |
Microfluidics |
||||
Researcher: Shyh-Dar Li Institution: University of British Columbia (UBC) Nanodelivery type
Targeting approach
Application
Disease model(s)
Protocols: Safety/pharmacology (Pre-GLP toxicity); Microfluidics |
University of British Columbia (UBC) |
Shyh-Dar Li |
Lipid-based |
Other: EPR effect, protein corona |
Drug delivery: Soluble molecules; Insoluble molecules |
Cancer (In vitro, Organoid, In vivo xenograft model, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) |
Safety/pharmacology (Pre-GLP toxicity) |
||
Researcher: Michel Meunier Institution: Polytechnique Montreal Nanodelivery type
Targeting approach
Application
Disease model(s)
|
Polytechnique Montreal |
Michel Meunier |
Lipid-based Inorganic |
Active targeting: Antibody or antibody fragments Physical targeting: Light sensitive |
Drug delivery: Soluble molecules Gene delivery: siRNA, mRNA/samRNA |
Cancer (In vitro) Other: ophthalmology (In vitro) |
|||
Researcher: Raymond Reilly Institution: University of Toronto Nanodelivery type
Targeting approach
Application
Disease model(s)
Protocols: Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing Instrumentation: Radioisotope measurement and small animal imaging systems (SPECT and PET) Auxiliary expertise: Regulatory science |
University of Toronto |
Raymond Reilly |
Inorganic |
Other: Local intratumoural infusion or implantation of gold nanoparticles |
Other: Radioisotope delivery |
Cancer (In vitro) |
Safety/pharmacology (Pre-GLP toxicity); Pre-GMP & GMP manufacturing |
Radioisotope measurement and small animal imaging systems (SPECT and PET) |
Regulatory science |
Researcher: Manish Sadarangani Institution: University of British Columbia (UBC) Nanodelivery type
Targeting approach
Application
Disease model(s)
Auxiliary expertise: Regulatory science |
University of British Columbia (UBC) |
Manish Sadarangani |
Other: bacterial outer membrane vesicles |
Active targeting: Antibody or antibody fragments |
Other: vaccine delivery |
Infectious diseases (Bacterial infections; In vitro [cells], In vivo [rodent]; BioSafety Level 2) |
Regulatory science |
||
Researcher: Gilbert Walker Institution: University of Toronto Nanodelivery type
Targeting approach
Application
Disease model(s)
Protocols: Microfluidics Instrumentation: high resolution mechanical and IR imaging |
University of Toronto |
Gilbert Walker |
Lipid-based |
Active targeting: Antibody or antibody fragments; Small molecule |
Drug delivery: Soluble molecules; Insoluble molecules |
Cancer (In vitro) |
Microfluidics |
high resolution mechanical and IR imaging |
|
Researcher: Xiao Yu (Shirley) Wu Institution: University of Toronto Nanodelivery type
Targeting approach
Application
Disease model(s)
Protocols: Safety/pharmacology Auxiliary expertise: Non-nano delivery systems |
University of Toronto |
Xiao Yu (Shirley) Wu |
Polymer-based |
Active targeting: Antibody or antibody fragments; Peptide; Small molecule |
Drug delivery: Soluble molecules; Insoluble molecules |
Cancer (In vitro, Organoid, In vivo orthotopic model, In vivo syngeneic model, In vivo metastatic model) |
Safety/pharmacology |
Non-nano delivery systems |